CIP2A elevation

In conclusion, CIP2A could interact with AKT1 to promote the malignant biological behaviors of OSCC cells by upregulating the GSK-3β/β-catenin pathway. These findings may provide a targeted therapy for OSCC treatment.

Our findings highlight that celastrol has therapeutic potential via inducing apoptosis of gastric cancer cells.

CIP2A expression could be a novel therapeutic strategy for chemoresistance in GC.

The reduction of CIP2A expression also enhanced the sensitivity of PCa cells toward Enzalutamide treatment...In summary, our data showed the existence of a novel regulation between CIP2A and AR protein levels, which is critical for promoting PCa malignancy. Thus, CIP2A could serve as a therapeutic target for PCa.

In summary, these results demonstrate that CIP2A directly interacts with TopBP1 and coordinates DNA-damage induced mitotic checkpoint and proliferation, thereby driving BLBC initiation and progression. SMAPs could serve as a surrogate therapeutic strategy to inhibit the oncogenic activity of CIP2A in BLBCs.